Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus.
about
A new strategy to fight antimicrobial resistance: the revival of old antibioticsProspective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureusUrinary tract infection in the neurogenic bladderIncreased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activityInhibition of Antibiotic-Resistant Staphylococcus aureus by the Broad-Spectrum Dihydrofolate Reductase Inhibitor RAB1Methylfolate Trap Promotes Bacterial Thymineless Death by Sulfa DrugsTreatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinicNewly formed cystic lesions for the development of pneumomediastinum in Pneumocystis jirovecii pneumonia.Cotrimoxazole - optimal dosing in the critically ill.Molecular epidemiology and antimicrobial resistance of methicillin-resistant Staphylococcus aureus bloodstream isolates in Taiwan, 2010Successful treatment for carriage of methicillin-resistant Staphylococcus aureus and importance of follow-upVascular catheter-associated infections: a microbiological and therapeutic update.Bacterial conversion of folinic acid is required for antifolate resistance.Trends in antibiotic susceptibility patterns and epidemiology of MRSA isolates from several hospitals in Riyadh, Saudi Arabia.Clinical management of diabetic foot infection: diagnostics, therapeutics and the future.Epidemiology of antimicrobial resistance in bloodstream infections.The evaluation and treatment of complicated skin and skin structure infections.Emergence of a community-associated methicillin-resistant Staphylococcus aureus strain with a unique resistance profile in Southwest Nigeria.Diagnosis and management of community-associated MRSA infections in children.Invasive community-associated MRSA infections: epidemiology and antimicrobial management.Advances in the diagnosis and management of pediatric osteomyelitis.Revisiting "older" antimicrobials in the era of multidrug resistance.Methicillin-resistant Staphylococcus aureus (MRSA) infections among HIV-infected persons in the era of highly active antiretroviral therapy: a review of the literature.Current and prospective treatments for multidrug-resistant gram-positive infections.Trimethoprim-sulfamethoxazole monotherapy should not be used for treatment of severe methicillin-resistant Staphylococcus aureus infections.In vitro and in vivo properties of dihydrophthalazine antifolates, a novel family of antibacterial drugs.Classifying compound mechanism of action for linking whole cell phenotypes to molecular targets.Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis.Autoinducer2 affects trimethoprim-sulfamethoxazole susceptibility in avian pathogenic Escherichia coli dependent on the folate synthesis-associate pathway.Antibiotic Dosing in Sustained Low-Efficiency Dialysis in Critically Ill Patients
P2860
Q21131083-E2F2AEE5-070C-4C3D-B98E-8C549BE3B695Q24678579-B2CD1CD0-CEDE-4E71-86D6-F986C0C753A6Q26767308-118444C5-56D3-4589-9281-4BA8E715619CQ27653751-E82E6338-0127-439E-9B83-5051A232FB79Q27663178-CD8F4316-72E7-4446-87A3-C2297A1B8678Q28552781-2640C6E5-CFA7-438E-8687-5BBBFBBC4A74Q33264142-F151725B-06E9-4D14-B236-0A40781B30DDQ33511054-83E08495-B9A8-42B0-B32A-1D8721909EB1Q33652427-346B28A1-D79D-4669-B8A5-EBE85070D6DCQ33812571-564E4903-B610-4D5E-A859-2497B8536BF4Q34108643-B680C77B-D528-4202-B80F-11BDAE4D8E49Q34585059-6D467A72-20E2-47EF-912E-76F934A6CFA5Q34869548-813AA889-75F9-4D3F-BD02-375A17C7BC44Q35241405-E2BA6A23-8D40-453E-945E-F8487EFC8514Q36723810-95B5C980-B631-4311-9AFE-F9653B7E4635Q36913239-B2D3D99F-D0B8-4829-867B-30303C7AFEACQ37111836-1FDEB560-1D8A-482C-BE38-7B196247BE93Q37333611-DB981D21-A08C-4C3F-9137-0EE03698257CQ37682916-005B6C17-B8C1-4A3D-A040-0CC996C164B8Q37800939-7AA99BC8-C6D7-40A3-910F-F0A2EE1349E4Q37905654-2A7B9B40-1F60-4FE7-9E7C-ADE96CEB3AEBQ37933412-5E4C1C9A-59D7-410F-A0B2-78E3FDB21C14Q37978658-2E997ACA-CB26-42C3-9E45-405E91768D04Q38123255-2DACBF2C-299E-4899-BA82-7D4383676250Q41117376-5C4B6FDE-AC67-4EF6-8EF2-54F2954C93CAQ42095872-DD8C0E9C-9388-4D48-8EE7-538836023146Q43103490-8F4671FB-88A7-4707-B46C-EF266EC84A47Q46456918-44B23557-B42A-4DB0-82BD-CFD9CDB55A5AQ50103280-9CDB0E57-2F0F-415C-823F-A1217D830D57Q57169898-652B379B-0E35-47DA-A24C-96B466A5B01B
P2860
Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Trimethoprim-sulfamethoxazole ...... sistant Staphylococcus aureus.
@ast
Trimethoprim-sulfamethoxazole ...... sistant Staphylococcus aureus.
@en
Trimethoprim-sulfamethoxazole ...... sistant Staphylococcus aureus.
@nl
type
label
Trimethoprim-sulfamethoxazole ...... sistant Staphylococcus aureus.
@ast
Trimethoprim-sulfamethoxazole ...... sistant Staphylococcus aureus.
@en
Trimethoprim-sulfamethoxazole ...... sistant Staphylococcus aureus.
@nl
prefLabel
Trimethoprim-sulfamethoxazole ...... sistant Staphylococcus aureus.
@ast
Trimethoprim-sulfamethoxazole ...... sistant Staphylococcus aureus.
@en
Trimethoprim-sulfamethoxazole ...... sistant Staphylococcus aureus.
@nl
P2093
P2860
P1433
P1476
Trimethoprim-sulfamethoxazole ...... sistant Staphylococcus aureus.
@en
P2093
Craig A Martin
Martin E Evans
Robert P Rapp
Shellee A Grim
P2860
P304
P356
10.1592/PHCO.25.2.253.56956
P407
P577
2005-02-01T00:00:00Z